TrialCell reports. Medicine2024

A phase 2 trial of gemcitabine plus toripalimab for cisplatin-ineligible patients with recurrent or metastatic nasopharyngeal carcinoma.

Xiong Zou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.